Cellular and molecular effects of thiazolidinediones on bone cells: A review

International Journal of Biochemistry and Molecular Biology

Volumn 2, Issue 3, 2011, Pages 240-246

  Mabilleau, Guillaume ^a   Chappard, Daniel ^a   Baslé, Michel F ^a  

^a UNIVERSITÉ D'ANGERS   (France)

Author keywords

Diabetes mellitus; Osteoblast; Osteoclast; Osteocyte; Ppary; Thiazolidinediones

Indexed keywords

ENGLITAZONE; GLITAZONE DERIVATIVE; LOBEGLITAZONE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADIPOGENESIS; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BONE REMODELING; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GENE LOCUS; GENETIC VARIABILITY; HUMAN; INSULIN SENSITIVITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROMOTER REGION; PROTEIN BINDING; REVIEW; SEX DIFFERENCE;

EID: 84855957644     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B and Viberti G. Glycemic durability of rosiglitazone, metformin, or gly-buride monotherapy. N Engl J Med 2006; 355: 2427-2443.
3. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B and Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.
4. Douglas IJ, Evans SJ, Pocock S and Smeeth L. The risk of fractures associated with thia-zolidinediones: a self-controlled case-series study. PLoS Med 2009; 6: e1000154.
5. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP and Viberti G. Rosiglita-zone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31: 845-851.
6. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, Jr., Vaughn DJ, Nessel L, Selby J and Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
7. Ren D, Collingwood TN, Rebar EJ, Wolffe AP and Camp HS. PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002; 16: 27-32.
8. Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG and Glass CK. Interactions controlling the assembly of nuclear-receptor het-erodimers and co-activators. Nature 1998; 395: 199-202.
9. Luconi M, Cantini G and Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer? Steroids 2010; 75: 585-594.
10. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Leh-mann JM, Wisely GB, Willson TM, Kliewer SA and Milburn MV. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999; 3: 397-403.
11. Nagy L, Tontonoz P, Alvarez JG, Chen H and Evans RM. Oxidized LDL regulates macro-phage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-240.
12. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM and Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-812.
13. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC and Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adi-pocyte differentiation. Cell 1995; 83: 813-819.
14. Davies SS, Pontsler AV, Marathe GK, Harrison KA, Murphy RC, Hinshaw JC, Prestwich GD, Hilaire AS, Prescott SM, Zimmerman GA and McIntyre TM. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem 2001; 276: 16015-16023.
15. Lehmann JM, Moore LB, Smith-Oliver TA, Wilki-son WO, Willson TM and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
16. Hofbauer LC, Brueck CC, Singh SK and Dobnig H. Osteoporosis in patients with diabetes mel-litus. J Bone Miner Res 2007; 22: 1317-1328.
17. Meymeh RH and Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 2007; 177: 723-724.
18. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strot-meyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB and Cummings SR. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-3354.
19. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J and Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmeno-pausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92: 1305-1310.
20. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N and Guvener Demirag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmeno-pausal diabetic women. J Clin Endocrinol Me-tab 2007; 92: 3523-3530.
21. Ton FN, Gunawardene SC, Lee H and Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005; 20: 464-470.
22. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K and Takeuchi Y. Thia-zolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999; 140: 5060-5065.
23. Yamato H, Okazaki R, Ishii T, Ogata E, Sato T, Kumegawa M, Akaogi K, Taniguchi N and Ma-tsumoto T. Effect of 24R,25-dihydroxyvitamin D3 on the formation and function of osteo-clastic cells. Calcif Tissue Int 1993; 52: 255-260.
24. Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD and Gallagher JA. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007; 40: 149-159.
25. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA and Marshak DR. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 2000; 275: 14388-14393.
26. Wan Y, Chong LW and Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007; 13: 1496-1503.
27. Wei W, Wang X, Yang M, Smith LC, Dechow PC, Sonoda J, Evans RM and Wan Y. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 2010; 11: 503-516.
28. Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, Ke HZ and Brown TA. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 2006; 39: 796-806.
29. Bergfeld SA and DeClerck YA. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010; 29: 249-261.
30. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM and Morris DC. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996; 50: 1087-1094.
31. Yamashita A, Takada T, Nemoto K, Yamamoto G and Torii R. Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage. FEBS Lett 2006; 580: 4121-4125.
32. Viccica G, Francucci CM and Marcocci C. The role of PPARgamma for the osteoblastic differentiation. J Endocrinol Invest 2010; 33: 9-12.
33. Lecka-Czernik B, Moerman EJ, Grant DF, Leh-mann JM, Manolagas SC and Jilka RL. Divergent effects of selective peroxisome prolifera-tor-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 2376-2384.
34. Rzonca SO, Suva LJ, Gaddy D, Montague DC and Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145: 401-406.
35. Moreau MF, Libouban H, Audran MJY and Chappard D. Thiazolidinediones modify nuclear heterochromatin architecture. J Bone Miner Res 2008; 23.
36. Parfitt AM. The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption--bone flow theory. Clin Orthop Relat Res 1977; 236-247.
37. Soroceanu MA, Miao D, Bai XY, Su H, Goltz-man D and Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/ osteocyte apoptosis. J Endocrinol 2004; 183: 203-216.
38. Mabilleau G, Mieczkowska A and Edmonds ME. Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet Med 2010; 27: 925-932.
39. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F and Ando S. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with perox-isome proliferator-activated receptor gamma signaling in breast cancer cells. Clin Cancer Res 2005; 11: 6139-6147.
40. Foryst-Ludwig A, Clemenz M, Hohmann S, Hartge M, Sprang C, Frost N, Krikov M, Bhanot S, Barros R, Morani A, Gustafsson JA, Unger T and Kintscher U. Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. PLoS Genet 2008; 4: e1000108.
41. Fain JN, Cowan GS, Buffington C, Andersen RN, Pouncey L and Bahouth SW. Regulation of leptin release by troglitazone in human adipose tissue. Metabolism 2000; 49: 1485-1490.
42. Williams LB, Fawcett RL, Waechter AS, Zhang P, Kogon BE, Jones R, Inman M, Huse J and Considine RV. Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab 2000; 85: 2678-2684.
43. Reid IR, Cornish J and Baldock PA. Nutrition-related peptides and bone homeostasis. J Bone Miner Res 2006; 21: 495-500.
44. Cornish J, Callon KE and Reid IR. Insulin increases histomorphometric indices of bone formation In vivo. Calcif Tissue Int 1996; 59: 492-495.
45. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A and Rosen CJ. Activation of perox-isome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007; 148: 903-911.
46. Cornish J, Callon KE, King AR, Cooper GJ and Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 1998; 275: E694-699.
47. Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K and Wulff EM. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome prolifera-tor-activated receptor (PPAR-gamma) agonist balaglitazone. Eur J Pharmacol 2008; 596: 173-179.
48. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H and Lazar MA. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem 1998; 273: 32679-32684.
49. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA and Lehmann JM. The structure-activity relationship between peroxisome pro-liferator-activated receptor gamma agonism and the antihyperglycemic activity of thia-zolidinediones. J Med Chem 1996; 39: 665-668.